Sarilumab

Drug Profile

Sarilumab

Alternative Names: Anti-IL 6 receptor antibody; Anti-interleukin 6 receptor antibody; REGN-88; SAR-153191

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Phase II Juvenile rheumatoid arthritis; Uveitis
  • Discontinued Ankylosing spondylitis

Most Recent Events

  • 16 Nov 2016 Efficacy data from the phase III SARIL-RA-MONARCH trial in Rheumatoid arthritis released by Regeneron Pharmaceuticals
  • 10 Nov 2016 Sanofi-aventis recherche & développement initiates a phase II trial for Juvenile rheumatoid arthritis in Spain (SC) (EudraCT2015-004000-35)
  • 01 Nov 2016 Sanofi completes the SARIL-RA-HARUKA trial in Rheumatoid arthritis in Japan (NCT02373202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top